Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma

Albert Grinshpun; Yonaton Zarbiv; Jason Roszik; Vivek Subbiah; Ayala Hubert

doi:10.1159/000496018

Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma

Albert Grinshpun, Yonaton Zarbiv, Jason Roszik, Vivek Subbiah, Ayala Hubert

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Pancreatic adenocarcinoma (PDAC) has a grim prognosis. Molecular and genomic analyses revealed that the striking majority of these tumors are driven by KRAS mutation, currently not amenable to targeted therapy. However, other driver mutations were found in a small fraction of patients. Herein we report of 3 cases of patients with metastatic PDAC and wildtype KRAS, found to harbor BRAF or RET pathogenic alterations. The patients were treated with targeted therapies with variable success. In our opinion, those proof-of-concept cases argue in favor of additional research and clinical trials' effort in this small but significant PDAC population with uncommon driver mutations.

Original language	English (US)
Pages (from-to)	7-13
Number of pages	7
Journal	Case Reports in Oncology
Volume	12
Issue number	1
DOIs	https://doi.org/10.1159/000496018
State	Published - Jan 1 2019

Keywords

BRAF
KRAS
Pancreatic adenocarcinoma
RET
Targeted therapy

ASJC Scopus subject areas

Oncology

MD Anderson CCSG core facilities

Clinical Trials Office

Access to Document

10.1159/000496018

Cite this

@article{973ec6e148ee4bb2839434b68bae3d81,

title = "Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma",

abstract = "Pancreatic adenocarcinoma (PDAC) has a grim prognosis. Molecular and genomic analyses revealed that the striking majority of these tumors are driven by KRAS mutation, currently not amenable to targeted therapy. However, other driver mutations were found in a small fraction of patients. Herein we report of 3 cases of patients with metastatic PDAC and wildtype KRAS, found to harbor BRAF or RET pathogenic alterations. The patients were treated with targeted therapies with variable success. In our opinion, those proof-of-concept cases argue in favor of additional research and clinical trials' effort in this small but significant PDAC population with uncommon driver mutations.",

keywords = "BRAF, KRAS, Pancreatic adenocarcinoma, RET, Targeted therapy",

author = "Albert Grinshpun and Yonaton Zarbiv and Jason Roszik and Vivek Subbiah and Ayala Hubert",

note = "Publisher Copyright: {\textcopyright} 2019 The Author(s). Published by S. Karger AG, Basel.",

year = "2019",

month = jan,

day = "1",

doi = "10.1159/000496018",

language = "English (US)",

volume = "12",

pages = "7--13",

journal = "Case Reports in Oncology",

issn = "1662-6575",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - Beyond KRAS

T2 - Practical Molecular Targets in Pancreatic Adenocarcinoma

AU - Grinshpun, Albert

AU - Zarbiv, Yonaton

AU - Roszik, Jason

AU - Subbiah, Vivek

AU - Hubert, Ayala

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Pancreatic adenocarcinoma (PDAC) has a grim prognosis. Molecular and genomic analyses revealed that the striking majority of these tumors are driven by KRAS mutation, currently not amenable to targeted therapy. However, other driver mutations were found in a small fraction of patients. Herein we report of 3 cases of patients with metastatic PDAC and wildtype KRAS, found to harbor BRAF or RET pathogenic alterations. The patients were treated with targeted therapies with variable success. In our opinion, those proof-of-concept cases argue in favor of additional research and clinical trials' effort in this small but significant PDAC population with uncommon driver mutations.

AB - Pancreatic adenocarcinoma (PDAC) has a grim prognosis. Molecular and genomic analyses revealed that the striking majority of these tumors are driven by KRAS mutation, currently not amenable to targeted therapy. However, other driver mutations were found in a small fraction of patients. Herein we report of 3 cases of patients with metastatic PDAC and wildtype KRAS, found to harbor BRAF or RET pathogenic alterations. The patients were treated with targeted therapies with variable success. In our opinion, those proof-of-concept cases argue in favor of additional research and clinical trials' effort in this small but significant PDAC population with uncommon driver mutations.

KW - BRAF

KW - KRAS

KW - Pancreatic adenocarcinoma

KW - RET

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85059905243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059905243&partnerID=8YFLogxK

U2 - 10.1159/000496018

DO - 10.1159/000496018

M3 - Article

C2 - 30792639

AN - SCOPUS:85059905243

SN - 1662-6575

VL - 12

SP - 7

EP - 13

JO - Case Reports in Oncology

JF - Case Reports in Oncology

IS - 1

ER -

Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this